ePrints

Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases

Lookup NU author(s): Professor Jane Endicott, Professor Martin NobleORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Indirubin is the active ingredient of Danggui Longhui Wan, a mixture of plants that is used in traditional Chinese medicine to treat chronic diseases. Here we identify indirubin and its analogues as potent inhibitors of cyclin-dependent kinases (CDKs), The crystal structure of CDK2 in complex with indirubin derivatives shows that indirubin interacts with the kinase's ATP-binding site through van der Waals interactions and three hydrogen bonds. Indirubin-3'-monoxime inhibits the proliferation of a large range of cells, mainly through arresting the cells in the G2/M phase of the cell cycle. These results have implications for therapeutic optimization of indigoids.

Publication metadata

Author(s): Hoessel R, Leclerc S, Endicott JA, Noble MEM, Lawrie A, Tunnah P, Leost M, Damiens E, Marie D, Marko D, Niederberger E, Tang WC, Eisenbrand G, Meijer L

Publication type: Article

Publication status: Published

Journal: Nature cell biology

Year: 1999

Volume: 1

Issue: 1

Pages: 60-67

Print publication date: 01/05/1999

ISSN (print): 1465-7392

ISSN (electronic): 1476-4679

Publisher: Nature Publishing Group

URL: http://dx.doi.org/10.1038/9035

DOI: 10.1038/9035

Altmetrics

Share